Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working ...

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...